Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us a call? We're coming up on the 100th episode of this podcast, and we're using the occasion to actualize our long-held dream of running a call-in show. Dial us at 617-517-6130 and leave a message with any question you'd like us to answer on the podcast, and you may just hear it on air in the coming weeks.
What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.
STAT's Matthew Herper joins us to dig into the history of the infamous pain drug Vioxx and a new effort to bring it back as a rare disease treatment. Then, we discuss how the synthetic biology industry is growing up and getting corporate. Finally, health care journalist Maggie Fox dials in to explain her deep dive on venture capital in biotech.
What do we talk about when we talk about "vape"? Are there limits to business of DNA testing? And how hard is it to get yourself CRISPR'd? STAT's Megan Thielking joins the gang to break down a major week of news in the world of vaping and STAT's Sharon Begley relates the story of a desperate patient seeking off-the-books genome editing and its implications for the future of medical research.